Damora Therapeutics annual free cash flow
2021
2022
Damora Therapeutics Free Cash Flow (FCF) History (DMRA)
Damora Therapeutics reported −$43.1M in free cash flow for fiscal 2022, an increase of $9.4M from the previous fiscal year.
View full Damora Therapeutics company overviewDamora Therapeutics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2022 | 2022-12-31 | −$43.1M | $9.4M | — | — |
| 2021 | 2021-12-31 | −$52.5M | — | — | — |
Damora Therapeutics quarterly free cash flow
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q4 2022 | 2022-12-31 | −$11.5M | $6.3M | — | — |
| Q3 2022 | 2022-09-30 | −$10.0M | −$779,000 | — | — |
| Q2 2022 | 2022-06-30 | −$14.9M | −$3.6M | — | — |
| Q1 2022 | 2022-03-31 | −$6.8M | $7.4M | — | — |
| Q4 2021 | 2021-12-31 | −$17.8M | — | — | — |
| Q3 2021 | 2021-09-30 | −$9.2M | — | — | — |
| Q2 2021 | 2021-06-30 | −$11.3M | — | — | — |
| Q1 2021 | 2021-03-31 | −$14.2M | — | — | — |
Damora Therapeutics free cash flow growth trends
Damora Therapeutics's latest reported quarter, Q4 2022, generated −$11.5M in free cash flow, an increase of $6.3M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Damora Therapeutics filings at SEC.gov ↗